

# PROTECT

**First published:** 26/06/2013

**Last updated:** 14/01/2025

Network

## Network identification

### Network ID

4199

---

### Network countries

- ☐ Belgium
  - ☐ Denmark
  - ☐ France
  - ☐ Germany
  - ☐ Italy
  - ☐ Netherlands
  - ☐ Poland
  - ☐ Spain
  - ☐ Sweden
  - ☐ Switzerland
  - ☐ United Kingdom
- 

### Network website

<https://www.imi-protect.eu>

---

## ENCePP partner

No

## Network description

[PROJECT NOW CLOSED] PROTECT was a public-private European project funded by the Innovative Medicines Initiative Joint Undertaking. It comprised a 5 year research programme to address limitations of current methods in the field of pharmacoepidemiology and pharmacovigilance. The European Medicines Agency was the coordinator and Glaxo Smith Kline was the deputy coordinator of this multi-national consortium of 31 partners. The goal was to strengthen the monitoring of the benefit/risk of medicines in Europe. This was achieved by developing a set of innovative tools and methods to improve the early detection of safety signals, enhance direct data collection from consumers and provide for a continuous benefit/risk monitoring of medicines. In addition, a methodological framework of pharmacoepidemiology studies was developed aiming at increasing the usefulness and reliability of these studies for benefit/risk assessment. All methods were tested to demonstrate their usefulness and applicability. This network was an ENCePP partner.

## Network details

### Network primary therapeutic area:

- Other

---

### Network funding:

- • EU institutional research programme

## Contact

placeholder placeholder placeholder@placeholder.com



[placeholder@placeholder.com](#)